Item 8.01 Other Events

On January 28, 2022, Catalyst issued a press release reporting that the U.S. Court of Appeals for the 11th Circuit has issued a mandate directing the District Court that heard Catalyst's claim against the FDA to enter summary judgement in favor of Catalyst in its lawsuit against the FDA, thereby vacating the FDA's approval of Ruzurgi® (Jacobus Pharmaceutical Company's amifampridine product).

A copy of the Company's press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d)  Exhibits



99.1      Press release issued by the Company on January 28, 2022.

104     Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses